 |
|
  |
BodyTite™ LiposuctionBodyTite™ liposuction is the new revolutionary body contouring procedure made available at bodySCULPT® , New York City. This is a radiofrequency assisted liposuction (RFAL) procedure, which has been much applauded for its unsurpassed safety, effectiveness and painless treatment. The procedure which has met with the approval of experienced plastic surgeons, is available for both men and women looking for a well contoured and attractive body with minimal post-surgical downtime. Innovative Liposuction Procedure Using BodyTite™At bodySCULPT® , our accomplished surgeons utilize the varied features of the innovative BodyTite™ device to remove excess fat deposits from your body. The compact handheld device is able to firm, shape the body and reduce wrinkles without surgery, scars, and painful injections unlike other types of liposuction. Specialists at bodySCULPT® are here to help patients who need treatment for specific areas of their body such as the face, saddle bags, chin, inner thighs, buttocks, love handles, abdominal areas, hips, knees, and more.The various inbuilt safety measures include constant monitoring of skin temperature and emergency power cut-off feature, all of which make BodyTite™ liposuction superior to other liposuction procedures. Trust and AssuranceBodyTite™ liposuction is performed at our state-of-the-art outpatient surgical center in Manhattan, NYC. Always in the forefront for providing the best care and treatment, bodySCULPT® surgeons assure all of our patients a safe, painless and risk free solution at all times. For more information regarding the liposuction procedures we offer in Manhattan, NYC, please call 1-800-282-SCULPT(728578) or e-mail us at info@bodysculpt.com. BodyTite™ is a sophisticated device using patented radiofrequency assisted liposuction (RFAL) technology for effective body contouring and significant skin contraction. BodyTite™ is a new innovative technique that bodySCULPT® is bringing to it's patients. The plastic surgeons at bodySCULPT® have been selected to head the IRB study in New York for FDA approval. |
